We genotyped 15 Bacillus anthracis isolates from Chad, Africa, using multiple-locus variable-number tandem repeat analysis and three additional direct-repeat markers. We identified two unique genotypes that represent a novel genetic lineage in the A cluster. Chadian isolates were susceptible to 11 antibiotics and free of 94 antibiotic resistance genes.
FIG. 1. Dendrogram based on MLVA of eight markers of Chadian
B. anthracis strains and the diverse 88 genotypes reported by Keim et al. (13) . The dendrogram was generated by clustering using the unweighted-pair group method with arithmetic means. Note that genotype 25 has been removed from the analysis since this strain no longer possesses the pXO2 plasmid, resulting in missing data in the MLVA.
pXO1-aaT, and pXO2-at, were amplified by PCR according to the method of Keim et al. (13) and sequenced on an ABI Prism 3100 genetic analyzer (Applied Biosystems, Foster City, CA) with dRhodamine-labeled terminators. The sizes of the VNTR amplicons were compared to previously published allele sizes (13, 20) as well as to the 11 B. anthracis strain genome sequences from GenBank (http://www.ncbi.nlm.nih.gov).
Since comparisons of the sequence sizes to the fragment size data revealed minor size discrepancies (1 bp for vrrA, 3 bp for vrrC 1 , and a previously reported 3-bp shift in the pXO1 size [P. Keim, personal communication] [6] ), MLVA-8 fragment analysis of 88 diverse genotypes (13) and two Chadian isolates (isolate ChadA1, group VII, and isolate ChadA8, group VIII) was performed in the Keim genetics laboratory (Northern Arizona University) to ensure the comparability and accuracy of the raw VNTR scores from the Chadian strains with reference to those from the genotypes published by Keim et al. in 2000 (13) (Fig. 1) .
Three additional DR regions of the B. anthracis chromosome (markers AJ03, AA03, and AT07) were amplified by PCR as described previously (15) , except that an annealing temperature of 45°C was used. The sequences for the different markers were compared to each other by multiple sequence alignment with ClustalW (http://www.ch.embnet.org) and the numbers of DRs determined ( Table 2 ). The Sterne strain NCTC8234 was used as a control, and the positions of the DRs were matched to the complete nucleotide (nt) sequence of this strain (GenBank accession no. AE017225). In the Sterne strain, the AJ03 marker is characterized by a succession of two 40- 
The antibiotic susceptibilities of the Chadian B. anthracis isolates were measured in Müller-Hinton broth by using custom Sensititre susceptibility plates (Trek Diagnostics Systems, East-Grinstead, England, and MCS Diagnostics BV, JL Swalmen, The Netherlands), according to the CLSI guidelines (7) . To exclude the possibility that Chadian B. anthracis isolates possessed antibiotic resistance genes that were not phenotypically expressed in vitro, we screened for the presence of 94 gram-positive bacterial antibiotic resistance genes using a microarray (18) .
PCR analysis revealed that the 15 isolates were B. anthracis and positive for the pXO1 and pXO2 plasmids. The fragment sizes and DNA sequences for the eight MLVA markers were identical in all Chadian strains. The effective sizes and the corrected, normalized scores for the eight MLVA alleles of the Chadian strains are listed in Table 2 . Of note, this is the first report of a 133-bp allele in pXO2. Analysis by unweighted-pair group method using average linkages clustered samples into a new genetic group in the A branch according to Keim's classification system (A␤) (Fig. 1) (13) . We used the system proposed by Levy et al. (15) to classify the 15 B. anthracis isolates into two different, novel genotypic groups (VII and VIII) (Table 2). These groups are new since this combination of DRs within the three markers has yet to be reported for B. anthracis, and the five-DR pattern in the AT07 marker in all Chadian strains is unique. We found no obvious geographic clustering of group VII and VIII strains (Fig. 2) .
The Chadian isolates were susceptible to the antibiotics tested but displayed decreased susceptibilities to ceftiofur, erythromycin, and the combination quinupristin-dalfopristin and a slightly higher MIC for clindamycin (MIC, 0.5 g/ml) than the Sterne strain NCTC8234 (Table 2) .
Microarray-based analysis revealed that the strains were free of all antibiotic resistance genes tested except the ␤-lactamase genes bla1 and bla2, which are endogenous to B. anthracis but are not expressed (5) .
This study is the first to describe the genetic and physiological attributes of B. anthracis strains in Chad. Certainly, this region of Africa has been underrepresented in previous studies of the global genetic diversity of B. anthracis (13) . On a regional level, the identical MLVA genotypes of the Chadian strains indicate a high degree of genetic similarity among B. anthracis isolates within the country. This is supported by the existence of only two unique, closely related strains identified by the three additional DR markers (groups VII and VIII) and the absence of antibiotic resistance genes in all the tested isolates. Similarly, our data suggest a low level of phenotypic diversity as it relates to antibiotic resistance. The finding that (313) 229 (229) 162 (162) 580 (583) 532 (532) 158 (158) (15); groups VII and VIII are new groups. e MICs were determined in duplicate, and the MIC interpretive standards were those recommended in CLSI supplement M100-S15 (8). Antibiotics: GEN, gentamicin; ERY, erythromycin; CLI, clindamycin, SYN, quinupristin-dalfopristin; TET, tetracycline; CHL, chloramphenicol; CIP, ciprofloxacin; XNL, ceftiofur; VAN, vancomycin; PEN, penicillin; AMC, amoxicillin-clavulanic acid. The CLSI susceptibility breakpoints are as follows: for GEN, Յ4; for ERY, Յ0.5; for CLI, Յ0.5; for SYN, Յ1; for TET, Յ1; for CHL, Յ8; for CIP, Յ0.5; for VAN, Յ4; for PEN, Յ0.12; for AMC, Յ4/2. The CLSI susceptibility breakpoints for TET, CIP, and PEN are those recommended in CLSI supplement M100-S15 (8) . For GEN, ERY, CLI, SYN, CHL, VAN, and AMC, S. aureus susceptibility breakpoints are suggested since no susceptibility breakpoints were available for B. anthracis in the CLSI supplement (3, 4, 16) . No CLSI criteria for susceptibility were available for XNL. The CLSI resistance breakpoints are as follows: for GEN, Ն16; for ERY, Ն8; for CLI, Ն4; for SYN, Ն4; for CHL, Ն32; for VAN, Ն32; for PEN, Ն0.25; for AMC, Ն8/4. The resistance breakpoint for PEN is that recommended in CLSI supplement M100-S15 (8) . For GEN, ERY, CLI, SYN, CHL, VAN, and AMC, S. aureus resistance breakpoints are suggested since no resistance breakpoints were available for B. anthracis in the CLSI supplement (3, 14, 16) . No CLSI criteria for resistance were available for TET, CIP, or XNL.
f The vaccine strain Sterne 34F2 (NCTC8234) was used as a control.
Chadian isolates were susceptible to 11 antibiotics and free of antibiotic resistance genes is significant from a public health perspective and can be used for therapeutic measures in the treatment of people affected with B. anthracis in this country. From a global perspective, our MLVA and DR analysis showed that the Chadian strains displayed unique genetic signatures and are not closely related to any of the worldwide B. anthracis strains analyzed to date (6, 9, 10, 11, 13, 19, 20) . Indeed, the long branch lengths of the A␤ group indicate a considerable degree of evolutionary divergence for these two strains from the remaining B. anthracis isolates in the A lineage (Fig. 1) . In summary, our results provide a first look at the genetic diversity and antibiotic resistance patterns of this pathogen in Chad and can be useful for future epidemiological analyses of anthrax outbreaks in this region. 
